雲頂新耀-B(01952.HK)與A*ccelerate訂立授權許可協議
格隆匯1月14日丨雲頂新耀-B(01952.HK)發佈公吿,2022年1月13日,公司的全資附屬公司Everest SG(作為被授權人)與A*ccelerate(作為授權人)訂立授權許可協議,據此,授權人向Everest SG授出一項於授權技術項下的獨家、不可轉讓、可轉授權、附特許使用權費及可因故撤回的授權許可,以在全球範圍內利用授權產品用於治療冠狀病毒及其他疾病,並對授權技術進行改進。
根據披露,新加坡科技研究局(“A*STAR”)是新加坡領先的公共研發機構。通過開放創新,其與公共和私營部門的合作伙伴合作造福經濟和社會。作為一家科技組織,A*STAR是學術界和工業界之間的橋樑。A*STAR的研究為新加坡創造了經濟增長和就業機會,並通過醫療保健、城市生活和可持續性方面的社會成果來改善生活。A*STAR為廣泛的研究界和行業培養科學人才和領導者方面發揮着關鍵作用。A*STAR的研發活動涵蓋生物醫學科學到物理科學和工程,研究實體主要位於Biopolis和Fusionopolis。A*ccelerate為A*STAR下專注於授權引進的機構,以支持A*STAR授權其研究成果。EDDC為新加坡國家藥物發現及開發平台並由A*STAR管理。
董事認為,公司與A*ccelerate之間的戰略合作結合公司現有的COVID-19疫苗項目,將使公司的抗疫策略更加完善。公司希望對COVID-19提供一攬子服務,包括預防性疫苗和便於使用的治療藥物,繼而令公司能夠實現其目標,即在這個治療方法有限的時期內為患者提供這種新型口服抗病毒療法。公司於2021年9月與Providence Therapeutics Holdings Inc.就雙方在COVID-19疫苗的製造、開發及商業化方面的合作訂立授權許可協議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.